Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.


Journal

The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309

Informations de publication

Date de publication:
05 2021
Historique:
received: 24 06 2020
revised: 06 11 2020
accepted: 15 01 2021
pubmed: 29 3 2021
medline: 12 5 2021
entrez: 28 3 2021
Statut: ppublish

Résumé

The genetic basis of lacunar stroke is poorly understood, with a single locus on 16q24 identified to date. We sought to identify novel associations and provide mechanistic insights into the disease. We did a pooled analysis of data from newly recruited patients with an MRI-confirmed diagnosis of lacunar stroke and existing genome-wide association studies (GWAS). Patients were recruited from hospitals in the UK as part of the UK DNA Lacunar Stroke studies 1 and 2 and from collaborators within the International Stroke Genetics Consortium. Cases and controls were stratified by ancestry and two meta-analyses were done: a European ancestry analysis, and a transethnic analysis that included all ancestry groups. We also did a multi-trait analysis of GWAS, in a joint analysis with a study of cerebral white matter hyperintensities (an aetiologically related radiological trait), to find additional genetic associations. We did a transcriptome-wide association study (TWAS) to detect genes for which expression is associated with lacunar stroke; identified significantly enriched pathways using multi-marker analysis of genomic annotation; and evaluated cardiovascular risk factors causally associated with the disease using mendelian randomisation. Our meta-analysis comprised studies from Europe, the USA, and Australia, including 7338 cases and 254 798 controls, of which 2987 cases (matched with 29 540 controls) were confirmed using MRI. Five loci (ICA1L-WDR12-CARF-NBEAL1, ULK4, SPI1-SLC39A13-PSMC3-RAPSN, ZCCHC14, ZBTB14-EPB41L3) were found to be associated with lacunar stroke in the European or transethnic meta-analyses. A further seven loci (SLC25A44-PMF1-BGLAP, LOX-ZNF474-LOC100505841, FOXF2-FOXQ1, VTA1-GPR126, SH3PXD2A, HTRA1-ARMS2, COL4A2) were found to be associated in the multi-trait analysis with cerebral white matter hyperintensities (n=42 310). Two of the identified loci contain genes (COL4A2 and HTRA1) that are involved in monogenic lacunar stroke. The TWAS identified associations between the expression of six genes (SCL25A44, ULK4, CARF, FAM117B, ICA1L, NBEAL1) and lacunar stroke. Pathway analyses implicated disruption of the extracellular matrix, phosphatidylinositol 5 phosphate binding, and roundabout binding (false discovery rate <0·05). Mendelian randomisation analyses identified positive associations of elevated blood pressure, history of smoking, and type 2 diabetes with lacunar stroke. Lacunar stroke has a substantial heritable component, with 12 loci now identified that could represent future treatment targets. These loci provide insights into lacunar stroke pathogenesis, highlighting disruption of the vascular extracellular matrix (COL4A2, LOX, SH3PXD2A, GPR126, HTRA1), pericyte differentiation (FOXF2, GPR126), TGF-β signalling (HTRA1), and myelination (ULK4, GPR126) in disease risk. British Heart Foundation.

Sections du résumé

BACKGROUND
The genetic basis of lacunar stroke is poorly understood, with a single locus on 16q24 identified to date. We sought to identify novel associations and provide mechanistic insights into the disease.
METHODS
We did a pooled analysis of data from newly recruited patients with an MRI-confirmed diagnosis of lacunar stroke and existing genome-wide association studies (GWAS). Patients were recruited from hospitals in the UK as part of the UK DNA Lacunar Stroke studies 1 and 2 and from collaborators within the International Stroke Genetics Consortium. Cases and controls were stratified by ancestry and two meta-analyses were done: a European ancestry analysis, and a transethnic analysis that included all ancestry groups. We also did a multi-trait analysis of GWAS, in a joint analysis with a study of cerebral white matter hyperintensities (an aetiologically related radiological trait), to find additional genetic associations. We did a transcriptome-wide association study (TWAS) to detect genes for which expression is associated with lacunar stroke; identified significantly enriched pathways using multi-marker analysis of genomic annotation; and evaluated cardiovascular risk factors causally associated with the disease using mendelian randomisation.
FINDINGS
Our meta-analysis comprised studies from Europe, the USA, and Australia, including 7338 cases and 254 798 controls, of which 2987 cases (matched with 29 540 controls) were confirmed using MRI. Five loci (ICA1L-WDR12-CARF-NBEAL1, ULK4, SPI1-SLC39A13-PSMC3-RAPSN, ZCCHC14, ZBTB14-EPB41L3) were found to be associated with lacunar stroke in the European or transethnic meta-analyses. A further seven loci (SLC25A44-PMF1-BGLAP, LOX-ZNF474-LOC100505841, FOXF2-FOXQ1, VTA1-GPR126, SH3PXD2A, HTRA1-ARMS2, COL4A2) were found to be associated in the multi-trait analysis with cerebral white matter hyperintensities (n=42 310). Two of the identified loci contain genes (COL4A2 and HTRA1) that are involved in monogenic lacunar stroke. The TWAS identified associations between the expression of six genes (SCL25A44, ULK4, CARF, FAM117B, ICA1L, NBEAL1) and lacunar stroke. Pathway analyses implicated disruption of the extracellular matrix, phosphatidylinositol 5 phosphate binding, and roundabout binding (false discovery rate <0·05). Mendelian randomisation analyses identified positive associations of elevated blood pressure, history of smoking, and type 2 diabetes with lacunar stroke.
INTERPRETATION
Lacunar stroke has a substantial heritable component, with 12 loci now identified that could represent future treatment targets. These loci provide insights into lacunar stroke pathogenesis, highlighting disruption of the vascular extracellular matrix (COL4A2, LOX, SH3PXD2A, GPR126, HTRA1), pericyte differentiation (FOXF2, GPR126), TGF-β signalling (HTRA1), and myelination (ULK4, GPR126) in disease risk.
FUNDING
British Heart Foundation.

Identifiants

pubmed: 33773637
pii: S1474-4422(21)00031-4
doi: 10.1016/S1474-4422(21)00031-4
pmc: PMC8062914
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

351-361

Subventions

Organisme : Wellcome Trust
ID : WT072952
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : U01 NS069208
Pays : United States
Organisme : Wellcome Trust
ID : WT084724MA
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 085475/B/08/Z
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : R01 NS100178
Pays : United States
Organisme : Medical Research Council
ID : MR/J006971/1
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : P30 DK072488
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS114045
Pays : United States
Organisme : British Heart Foundation
ID : RG/16/4/32218
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT088134/Z/09/A
Pays : United Kingdom
Organisme : BLRD VA
ID : I01 BX004672
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS086873
Pays : United States
Organisme : Wellcome Trust
ID : 085475/Z/08/Z
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : R01 NS103924
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS105150
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
PLoS One. 2015 Aug 25;10(8):e0136352
pubmed: 26305465
Nat Genet. 2015 Mar;47(3):291-5
pubmed: 25642630
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
Nat Genet. 2018 Nov;50(11):1505-1513
pubmed: 30297969
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Cell. 2016 Nov 17;167(5):1398-1414.e24
pubmed: 27863251
Nat Protoc. 2014 May;9(5):1192-212
pubmed: 24762786
Nat Genet. 2016 Mar;48(3):245-52
pubmed: 26854917
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Lancet. 1991 Jun 22;337(8756):1521-6
pubmed: 1675378
EMBO Mol Med. 2014 Jul 09;6(8):1028-42
pubmed: 25007800
PLoS Comput Biol. 2015 Apr 17;11(4):e1004219
pubmed: 25885710
Am J Hum Genet. 2016 Sep 1;99(3):762-769
pubmed: 27569546
Stroke. 2012 Dec;43(12):3161-7
pubmed: 23042660
Neurogenesis (Austin). 2017 May 23;4(1):e1313646
pubmed: 28596978
Brain. 2020 Feb 1;143(2):597-610
pubmed: 31968102
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16496-501
pubmed: 25369932
J Cereb Blood Flow Metab. 2016 Jan;36(1):143-57
pubmed: 25853907
Hum Mol Genet. 2018 Oct 15;27(20):3641-3649
pubmed: 30124842
Nat Genet. 2012 Feb 05;44(3):328-33
pubmed: 22306652
Clin Sci (Lond). 2017 Apr 1;131(7):515-531
pubmed: 28302914
Nat Genet. 2017 Jan;49(1):131-138
pubmed: 27918535
Nat Genet. 2012 Mar 18;44(4):369-75, S1-3
pubmed: 22426310
Nucleic Acids Res. 2018 Jan 4;46(D1):D1068-D1073
pubmed: 29156001
Sci Transl Med. 2018 Jul 4;10(448):
pubmed: 29973407
Lancet Neurol. 2016 Feb;15(2):174-184
pubmed: 26708676
Stroke. 2018 Apr;49(4):820-827
pubmed: 29535274
PLoS Genet. 2014 May 15;10(5):e1004383
pubmed: 24830394
Genome Biol. 2017 May 16;18(1):86
pubmed: 28506277
Bioinformatics. 2019 Nov 1;35(22):4851-4853
pubmed: 31233103
Nature. 2019 Aug;572(7771):614-619
pubmed: 31435015
Dev Dyn. 2017 Apr;246(4):275-284
pubmed: 27859941
Nat Genet. 2012 Jul 22;44(8):848-51
pubmed: 22820511
Stroke. 2003 Jun;34(6):1364-9
pubmed: 12714707
Nature. 2017 Oct 11;550(7675):204-213
pubmed: 29022597
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
Ann Neurol. 2017 Mar;81(3):383-394
pubmed: 27997041
Glia. 2018 Jan;66(1):175-190
pubmed: 29034508
Stroke. 2017 Sep;48(9):2405-2411
pubmed: 28765289
Nat Neurosci. 2016 Nov;19(11):1442-1453
pubmed: 27668389
Cell Tissue Res. 2019 Apr;376(1):137-141
pubmed: 30610452
Ann Neurol. 2018 Dec;84(6):934-939
pubmed: 30383316
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Nature. 2010 Aug 5;466(7307):707-13
pubmed: 20686565
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Brain. 2019 Oct 1;142(10):3176-3189
pubmed: 31430377
Bioinformatics. 2016 Oct 15;32(20):3207-3209
pubmed: 27318201
Nat Genet. 2015 Oct;47(10):1121-1130
pubmed: 26343387
Biometrics. 1999 Dec;55(4):997-1004
pubmed: 11315092
J Neurosci. 2014 Nov 12;34(46):15260-80
pubmed: 25392494
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Genet. 2017 Jan;49(1):54-64
pubmed: 27841878
J Neuroimaging. 2008 Jan;18(1):66-72
pubmed: 18190499
Sci Signal. 2014 Aug 12;7(338):ra76
pubmed: 25118328
Nat Genet. 2018 Feb;50(2):229-237
pubmed: 29292387
PLoS Genet. 2019 Oct 9;15(10):e1008431
pubmed: 31596850
Nat Genet. 2017 May;49(5):674-679
pubmed: 28346444
Nat Genet. 2012 Feb 19;44(3):247-50
pubmed: 22344220
Nat Commun. 2020 May 1;11(1):2175
pubmed: 32358547
Nat Commun. 2014 Mar 03;5:3413
pubmed: 24583950
Lancet Neurol. 2019 Jul;18(7):684-696
pubmed: 31097385
Nature. 2011 Sep 11;478(7367):103-9
pubmed: 21909115
Circ Cardiovasc Genet. 2015 Apr;8(2):398-409
pubmed: 25663218
Neurology. 2017 Oct 24;89(17):1829-1839
pubmed: 28954878
Genome Biol. 2016 Mar 31;17:61
pubmed: 27036880
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
N Engl J Med. 2009 Apr 23;360(17):1729-39
pubmed: 19387015
Nat Genet. 2018 Apr;50(4):524-537
pubmed: 29531354
Nat Genet. 2019 Feb;51(2):237-244
pubmed: 30643251
Circulation. 2007 Nov 6;116(19):2157-64
pubmed: 17967776
Int J Epidemiol. 2008 Dec;37(6):1220-6
pubmed: 18263651
Lancet Neurol. 2016 Jun;15(7):695-707
pubmed: 27068588
Am J Clin Nutr. 2016 Apr;103(4):965-78
pubmed: 26961927

Auteurs

Matthew Traylor (M)

Clinical Pharmacology and The Barts Heart Centre and NIHR Barts Biomedical Research Centre, Barts Health NHS Trust, William Harvey Research Institute, Queen Mary University of London, London, UK.

Elodie Persyn (E)

Department of Medical and Molecular Genetics, King's College London, London, UK.

Liisa Tomppo (L)

Department of Neurology, Helsinki University Hospital, Helsinki, Finland.

Sofia Klasson (S)

Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Vida Abedi (V)

Department of Molecular and Functional Genomics, Weis Center for Research, Geisinger Health System, Danville, PA, USA.

Mark K Bakker (MK)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands.

Nuria Torres (N)

Stroke Pharmacogenomics and Genetics, Sant Pau Institute of Research, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.

Linxin Li (L)

Centre for the Prevention of Stroke and Dementia, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.

Steven Bell (S)

Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Loes Rutten-Jacobs (L)

Product Development Personalized Health Care, F Hoffmann-La Roche, Basel, Switzerland.

Daniel J Tozer (DJ)

Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Christoph J Griessenauer (CJ)

Neuroscience Institute, Geisinger Health System, Danville, PA, USA; Institute of Neurointervention, Paracelsus Medical University, Salzburg, Austria.

Yanfei Zhang (Y)

Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA.

Annie Pedersen (A)

Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Pankaj Sharma (P)

Institute of Cardiovascular Research, Royal Holloway University of London, London, UK.

Jordi Jimenez-Conde (J)

Neurovascular Research Group, Department of Neurology of Hospital del Mar-IMIM (Institut Hospital del Mar d'Investigacions Mediques), Universitat Autonoma de Barcelona/DCEXS-Universitat Pompeu Fabra, Barcelona, Spain.

Tatjana Rundek (T)

Evelyn F McKnight Brain Institute, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.

Raji P Grewal (RP)

Neuroscience Institute, Saint Francis Medical Center, School of Health and Medical Sciences, Seton Hall University, South Orange, NJ, USA.

Arne Lindgren (A)

Department of Neurology, Skane University Hospital, Lund, Sweden; Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden.

James F Meschia (JF)

Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.

Veikko Salomaa (V)

Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland.

Aki Havulinna (A)

Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland; Institute for Molecular Medicine Finland (FIMM HiLIFE), Helsinki, Finland.

Christina Kourkoulis (C)

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Katherine Crawford (K)

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Sandro Marini (S)

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Braxton D Mitchell (BD)

Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA.

Steven J Kittner (SJ)

Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA; Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA.

Jonathan Rosand (J)

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Martin Dichgans (M)

Institute for Stroke and Dementia Research (ISD), LMU Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Christina Jern (C)

Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

Daniel Strbian (D)

Department of Neurology, Helsinki University Hospital, Helsinki, Finland; Clinical Neurosciences, University of Helsinki, Helsinki, Finland.

Israel Fernandez-Cadenas (I)

Stroke Pharmacogenomics and Genetics, Sant Pau Institute of Research, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; Neurovascular Research Laboratory and Neurovascular Unit, Institut de Recerca, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.

Ramin Zand (R)

Neuroscience Institute, Geisinger Health System, Danville, PA, USA.

Ynte Ruigrok (Y)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands.

Natalia Rost (N)

J Philip Kistler Stroke Research Center, Massachusetts General Hospital, Boston, MA, USA.

Robin Lemmens (R)

Experimental Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium; VIB Center for Brain & Disease Research, Department of Neurology, University Hospitals Leuven, Leuven, Belgium.

Peter M Rothwell (PM)

Centre for the Prevention of Stroke and Dementia, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.

Christopher D Anderson (CD)

Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Program in Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Joanna Wardlaw (J)

Centre for Clinical Brain Sciences, UK Dementia Research Institute and Row Fogo Centre for Research into the Ageing Brain, University of Edinburgh, Edinburgh, UK.

Cathryn M Lewis (CM)

Department of Medical and Molecular Genetics, King's College London, London, UK; Social, Genetic, and Developmental Psychiatry Centre, King's College London, London, UK.

Hugh S Markus (HS)

Clinical Neurosciences, University of Cambridge, Cambridge, UK. Electronic address: hsm32@medschl.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH